1FW

CASE 4-32095B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

September 16, 2004
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BOLD ET AL.

APPLICATION NO: 10/783,000 FILED: FEBRUARY 20, 2004

FOR: 7H-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

1

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

EP 682027A1 is substantially equivalent to U.S. Patents 5,686,457 and 6,096,749. WO 02/32872A1 is substantially equivalent to U.S. Patent Application US2004/0053908A1. Copies of these U.S. patents and U.S. Patent application publications pursuant to the waiver of requirement under 37 CFR 1.98(a)(2)(i) issued in the Official Gazette dated August 5, 2003, are not provided.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Attorney for Applicants

Lydia T. McNally

Reg. No. 36,214

Novartis Corporate Intellectual Property One Health Plaza, Building 430 East Hanover, NJ 07936-1080 (862) 778-7898

Date: august 16, 2004

FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-32095B APPLICATION NO. 10/783,000 APPLICANT BOLD ET AL. FILING DATE FEBRUARY 20, 2004

Group

SEP 1 6 2004 5

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,686,457	11/11/97	Traxler et al.			
	AB	6,096,749	8/1/00	Traxler et al.			
	AC	5,958,930	9/28/99	Gangjee			
	AD	5,877,178	3/2/99	Gangjee			
	AE						
	AF						
	AG						
	АН						
	ΑI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
АМ	98/07726	2/26/98	wo				
AN	97/02266	1/23/97	wo				
 AO	98/43973	10/8/98	WO (abstract only)				
AP	01/47507	7/5/01	wo				
AQ	99/65908	12/23/99	wo				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

			·
•		AR	U.S. Patent Application No. US 2004/0053908A1, Pub. Date March 18, 2004
		AS	Caravatti et al., "Pyrrolo[2,3-d]pyrimidine and Pyrazolo[3,4-d]pyrimidine Derivatives as Selective Inhibitors of the EGF Receptor Tyrosine Kinase," ACS Symposium series, 796, pp. 231-244 (2001)
		АТ	
	EXAMIN	ER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85)

1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-32095B APPLICATION NO. 10/783,000 APPLICANT BOLD ET AL. FILING DATE FEBRUARY 20, 2004

Group

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN	SLATION
	CA	0 795 556	9/17/97	EP			YES	NO
	СВ	98/06703	2/19/98	WO	_			
	 	97/47601	<u> </u>					
	CC		12/18/97	WO (abstract only)				
	CD	01/49688	7/12/01	wo				<u> </u>
	CE	95/33750	12/14/95	wo				
	CF	1 040 831	10/4/00	EP				
	CG	99/65909	12/23/99	wo				
	СН	01/53263	7/26/01	wo				
	CI	01/23389	4/5/01	WO				
	CJ							
	СК							
	CL							
	СМ							
	CN							
	СО							
	СР							
	CQ							
	CR							
	cs							
	СТ				-			
	CU							
	cv							
	cw							
	СХ							
	CY							
	CZ							 -
EXAMIN			<u> </u>	DATE CONSIDERED		l		

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.